Literature DB >> 18164881

Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains.

Misagh Alipour1, Majed Halwani, Abdelwahab Omri, Zacharias E Suntres.   

Abstract

Polymyxin B is a polycationic antibiotic effective in the treatment of Gram-negative bacterial infections. Systemic use of polymyxin B has been limited due to its toxicity, most notably nephrotoxicity, ototoxicity, and neuromuscular blockade. Entrapment of antibiotics in liposomes is known to enhance their antimicrobial activities while minimizing their toxic effects. In the present study, polymyxin B was incorporated into liposomes composed of either 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol (Chol) or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and Chol. The entrapment efficiency of sonicated liposomes containing DPPC/Chol (32.1+/-2.43%) was six-fold higher than that of liposomes containing POPC/Chol (5.35+/-0.32%). On the other hand, the entrapment efficiency of extruded DPPC/Chol liposomes (3.23+/-0.46%) was about 30% less than that of liposomes composed of POPC/Chol (5.10+/-0.37%). Incubation of extruded DPPC/Chol liposomes containing polymyxin B in serum at 37 degrees C resulted in a complete release of the antibiotic into the supernatant after 3h as compared to 6h in the case of POPC/Chol liposomes. Spontaneous release of polymyxin B from DPPC/Chol liposomes incubated in saline was significantly higher (66%) than that from POPC/Chol liposomes (24%) after 48h at 37 degrees C. With respect to the antimicrobial activities of the liposomal polymyxin B formulations, the MICs of sonicated DPPC/Chol liposomes against Gram-negative strains were generally lower when compared to free polymyxin B. Immunocytochemistry and electron transmission microscopic studies revealed that the penetration of polymyxin B into a resistant strain of Pseudomonas aeruginosa was higher following its administration as a liposomal formulation as compared to its conventional form. The combination of free drug and plain liposomes had an antibacterial activity similar to that of free antibiotic. These data suggest that incorporation of polymyxin B in liposomes could be useful in the management of Gram-negative infections induced by these microorganisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18164881     DOI: 10.1016/j.ijpharm.2007.11.035

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  24 in total

1.  Size-dependent biodistribution of thiol-organosilica nanoparticles and F4/80 protein expression in the genital tract of female mice after intravaginal administration.

Authors:  Aziz Awaad; Michihiro Nakamura
Journal:  Histochem Cell Biol       Date:  2021-03-03       Impact factor: 4.304

2.  Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.

Authors:  Jie He; Kamilia Abdelraouf; Kimberly R Ledesma; Diana S-L Chow; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2013-08-22       Impact factor: 5.283

Review 3.  Nanotechnology-based drug delivery systems for control of microbial biofilms: a review.

Authors:  Matheus Aparecido Dos Santos Ramos; Patrícia Bento Da Silva; Larissa Spósito; Luciani Gaspar De Toledo; Bruna Vidal Bonifácio; Camila Fernanda Rodero; Karen Cristina Dos Santos; Marlus Chorilli; Taís Maria Bauab
Journal:  Int J Nanomedicine       Date:  2018-02-27

4.  Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.

Authors:  Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

5.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

Review 6.  Emerging and re-emerging infectious disease in otorhinolaryngology.

Authors:  F Scasso; G Ferrari; G C DE Vincentiis; A Arosio; S Bottero; M Carretti; A Ciardo; S Cocuzza; A Colombo; B Conti; A Cordone; M DE Ciccio; E Delehaye; L Della Vecchia; I DE Macina; C Dentone; P DI Mauro; R Dorati; R Fazio; A Ferrari; G Ferrea; S Giannantonio; I Genta; M Giuliani; D Lucidi; L Maiolino; G Marini; P Marsella; D Meucci; T Modena; B Montemurri; A Odone; S Palma; M L Panatta; M Piemonte; P Pisani; S Pisani; L Prioglio; A Scorpecci; L Scotto DI Santillo; A Serra; C Signorelli; E Sitzia; M L Tropiano; M Trozzi; F M Tucci; L Vezzosi; B Viaggi
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-04       Impact factor: 2.124

7.  Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.

Authors:  Misagh Alipour; Zacharias E Suntres; Majed Halwani; Ali O Azghani; Abdelwahab Omri
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

8.  Preparation, characterization and in vitro antimicrobial activity of liposomal ceftazidime and cefepime against Pseudomonas aeruginosa strains.

Authors:  Ieda Maria Sapateiro Torres; Etiene Barbosa Bento; Larissa da Cunha Almeida; Luisa Zaiden Carvalho Martins de Sá; Eliana Martins Lima
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

9.  Enhanced bactericidal potency of nanoliposomes by modification of the fusion activity between liposomes and bacterium.

Authors:  Yufan Ma; Zhao Wang; Wen Zhao; Tingli Lu; Rutao Wang; Qibing Mei; Tao Chen
Journal:  Int J Nanomedicine       Date:  2013-06-28

Review 10.  Novel formulations for antimicrobial peptides.

Authors:  Ana Maria Carmona-Ribeiro; Letícia Dias de Melo Carrasco
Journal:  Int J Mol Sci       Date:  2014-10-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.